A randomized, double-blind, placebo-controlled, phase 3 study to assess the efficacy, safety and pharmacokinetics of Lebrikizumab compared to placebo in participants 6 months to <18 years of age with moderate-to-severe atopic dermatitis.

Principal Investigator

Brian Simmons

Study Number

STUDY02001748

Summary

The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to &lt;18 years of age with moderate-to-severe atopic dermatitis (AD).

Phase

III

Available at the following location(s)

• Lebanon

View more details at ClinicalTrials.gov

Do you need help with some of the labels on this page?
Read our glossary of terms